_256_384.jpg)
Drug Approval | April 27, 2026
Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Platform integrates VR simulations and AI-driven coaching to build job-ready skills in pharma manufacturing
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Move comes amid rising regulatory pressures
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
